CACLP - The largest IVD Expo & Conference

Are We in Store for More M&A in the Liquid Biopsy Space?

Industry news | 13 July, 2018 | CACLP

M&A activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.

Waltham, MA-based Exosome has developed the urine-based test ExoDx Prostate (IntelliScore) to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result.

“This is a very strategic acquisition for us as we also expand in the CAR-T cell marketplace, leveraging our growing critical mass in cell culture-focused product lines,” Charles Kummeth, president and CEO of Bio-Techne said in a release. “Following this acquisition, the company now sells solutions to the entire workflow of cancer: research, diagnostics and therapeutics.

Minneapolis, MN-based Bio-Techne said the transaction is expected to close in July or early August. The deal will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne said it expects to obtain prior to the closing of the acquisition.

Liquid Biopsy has always been a hot sector venture capitalists. For instance, Grail, which was spun off from San Diego-based, Illumina raised $1 billion in a series B round. The company brought in about $100 million in initial funding. Grail’s rival, Redwood City, CA-based Guardant Health raised $360 million in May of last year.

But now it seems as if the space is ripe for M&A. Over the past few years there have been several high-profile liquid biopsy acquisitions.

Earlir this month, Roche flexed its M&A muscle by making a play to pick up the remaining shares of Foundation Medicine for $2.4 billion. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January 2015 when Roche invested roughly $1.03 billion to acquire a majority interest in Foundation Medicine.

Precipio acquired Transgenomics last year and stressed the driving point behind the merger was the technology. Precipio became a public company through the acquisition.

And in 2016, Siemens acquired German Startup, Neo New Oncology. Through the acquisition, Siemens was able to obtain a NeOliquid test for the analysis of genomic profiles of solid tumors from a simple blood sample.

Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference